Mural Oncology plc (MURA NASDAQ) stock market data APIs
$2.5408
-0.08(-3.1%)
as of July 14, 2025
Try our APIs with
free plan!
Mural Oncology plc Financial Data Overview
Price chart is built with
Anychart
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
Prev. Close
2.5408
Open
2.4609
High
2.5894
Low
2.4609
52 wk Range
0.95-4.74
Market Cap
42 136 K
Shares Outstanding
17 269 K
EPS
-1.93
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Mural Oncology plc data using free add-ons & libraries
Get Mural Oncology plc Fundamental Data
Mural Oncology plc Fundamental data includes:
- Net Revenue:
- EBITDA: -135 096 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-20
- EPS/Forecast: -1.98
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mural Oncology plc News
New
BlackRock discloses 1.65% stake in Mural Oncology
DUBLIN - Investment management firm BlackRock (NYSE:BLK), Inc. has disclosed a 1.65% stake in Mural Oncology plc, according to a regulatory filing published Friday. The disclosure, made under Rule 8....
BlackRock discloses 1.65% stake in Mural Oncology
DUBLIN - Investment giant BlackRock (NYSE:BLK), Inc. has disclosed a 1.65% ownership position in Mural Oncology plc, according to a regulatory filing published Monday. The disclosure, made under Rule...
Mural Oncology Announces Number of Relevant Securities in Issue
WALTHAM, Mass. and DUBLIN, May 19, 2025 (GLOBE NEWSWIRE) -- In accordance with Rule 2.12 of the Irish Takeover Panel Act 1997, the Irish Takeover Rules 2022 (the “Irish Takeover Rules”), Mural O...
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis Continued demonstration of favorable tolerability pro...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
